Background: Beta-blockers (BB) have been shown to reduce hospital admissions and improve survival in chronic systolic heart failure (CHF), with mortality reduction being dose-related and starting early after BB initiation. However, general practitioners have generally been reluctant to up-titrate BB to the doses mandated by clinical trials.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Heart, Lung and Circulation
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2007 Published by Elsevier Inc.